Topical L. Reuteri in Children With Atopic Dermatitis

NCT ID: NCT04265716

Last Updated: 2020-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-13

Study Completion Date

2020-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety and efficacy of the probiotic L. reuteri vs control product as an adjuvant for improving the skin appearance of children with mild or moderate atopic dermatitis. All children will receive the standard of care. Half of the children will receive topical L. reuteri in emollient, while the other half will receive the standard of care plus control product

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AD if a very frequent allergic skin disorders in children. Produce a negative significant impact on quality of life and related costs. Recently the changes of skin microbiota had been related with inadequate evolution of atopic dermatitis.

L. reuteri had been identified with some effect to reduce skin inflammation and help to modulate inflammatory pathways on skin. Investigators expect using topical L. reuteri as adjuvant some improvement on skin appearance due to the mode of action previous referenced additionally to some potential changes on microbiome

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double blind, placebo controlled trial, 2 parallel arms. Children with mild or moderate atopic dermatitis will be randomly selected at the Pediatric Dermatologic Clinic-Hospital General GEA-Mexico if they fulfill selectioncriteria.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
This is a double-blinded study. All study staff, including the Principal Investigator and the persons performing the subject assessments, will be blinded during the study. Sealed individual treatment code envelopes will be kept at the clinic to be able to break the code if any emergency occurs, as judged by the Investigator. Tubes with interventions has the same exterior appearence. Emollient are similar in consistency and odour

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

L. reuteri

Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day

Group Type ACTIVE_COMPARATOR

Topical L. reeuteri

Intervention Type OTHER

Tubes with ointment containing L. reuteri DSM17938

Placebo

Rubbed into skin twice per day

Group Type PLACEBO_COMPARATOR

Topical L. reeuteri

Intervention Type OTHER

Tubes with ointment containing L. reuteri DSM17938

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical L. reeuteri

Tubes with ointment containing L. reuteri DSM17938

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children age 1 to 8 years old
* Atopic Dermatitis (AD) according to the criteria of Hanifin and Rajka
* SCORAD Index 15 to 50, inclusive
* Subjects whose parents or legal representative are willing to sign the informed consent
* When the child is 8, he/she must also give consent to participate in the study

Exclusion Criteria

* Use of phototherapy for atopic dermatitis
* Systemic or topic corticosteroids in tthe 30 days prior to the study
* Immunosuppressive or cytostatic drugs in the 2 months prior to the study
* Use of probiotics in the 2 weeks prior to the study
* Other allergic severe disease (asthma, allergic rhinitis)
* Systemic antibiotics in the four days prior to the study
* Fever (temperature\> 37.5 °C axillary or equivalent)
* Pathologies associated with immunodeficiency or cancer processes
* Dermatological diseases that may hinder the evaluation of atopic dermatitis or require the continued use of topical corticosteroids
* Subjects for whom any of the studies products are contraindicated according to their technical specifications
* Subjects who have participated in research studies with any products in the 3 months prior to the trial
Minimum Eligible Age

1 Year

Maximum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioGaia AB

INDUSTRY

Sponsor Role collaborator

Innovacion y Desarrollo de Estrategias en Salud

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pedro Gutierrez Castrellon

Head of Research for Mother-Child

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital General Dr. Manuel Gea Gonzalez

Mexico City, , Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pedro Gutierrez-Castrellon, MD, PhD

Role: CONTACT

+525540003000 ext. 1246

Guadalupe Maldonado-Colin, MSc

Role: CONTACT

+525540003000 ext. 1246

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pedro Gutierrez-Castrellon, MD, PhD

Role: primary

+525540003000 ext. 1246

Paola Juarez Valdez

Role: backup

+525540003000 ext. 1246

References

Explore related publications, articles, or registry entries linked to this study.

Amalia N, Orchard D, Francis KL, King E. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. Australas J Dermatol. 2020 May;61(2):e158-e173. doi: 10.1111/ajd.13186. Epub 2019 Nov 12.

Reference Type BACKGROUND
PMID: 31721162 (View on PubMed)

Yang W, Tu R, Hu Y, He T, Zhang W, Gu L, Liu H. Probiotics supplement for the prevention of eczema in children: Study protocol for a meta-analysis and systematic review. Medicine (Baltimore). 2019 Aug;98(34):e16957. doi: 10.1097/MD.0000000000016957.

Reference Type BACKGROUND
PMID: 31441896 (View on PubMed)

Yan DC, Hung CH, Sy LB, Lue KH, Shih IH, Yang CY, Chen LC, Sun HL, Lee MS, Chambard J, Tanguy J, Hughes-Formella B, Nutten S, Blanchard C. A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated Lactobacillus paracasei Supplement in Infants with Atopic Dermatitis Receiving Topical Corticosteroid Therapy. Skin Pharmacol Physiol. 2019;32(4):201-211. doi: 10.1159/000499436. Epub 2019 May 22.

Reference Type BACKGROUND
PMID: 31117100 (View on PubMed)

Li L, Han Z, Niu X, Zhang G, Jia Y, Zhang S, He C. Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-analysis. Am J Clin Dermatol. 2019 Jun;20(3):367-377. doi: 10.1007/s40257-018-0404-3.

Reference Type BACKGROUND
PMID: 30465329 (View on PubMed)

Navarro-Lopez V, Ramirez-Bosca A, Ramon-Vidal D, Ruzafa-Costas B, Genoves-Martinez S, Chenoll-Cuadros E, Carrion-Gutierrez M, Horga de la Parte J, Prieto-Merino D, Codoner-Cortes FM. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018 Jan 1;154(1):37-43. doi: 10.1001/jamadermatol.2017.3647.

Reference Type BACKGROUND
PMID: 29117309 (View on PubMed)

Prakoeswa CRS, Herwanto N, Prameswari R, Astari L, Sawitri S, Hidayati AN, Indramaya DM, Kusumowidagdo ER, Surono IS. Lactobacillus plantarum IS-10506 supplementation reduced SCORAD in children with atopic dermatitis. Benef Microbes. 2017 Oct 13;8(5):833-840. doi: 10.3920/BM2017.0011. Epub 2017 Oct 12.

Reference Type BACKGROUND
PMID: 29022387 (View on PubMed)

Wu YJ, Wu WF, Hung CW, Ku MS, Liao PF, Sun HL, Lu KH, Sheu JN, Lue KH. Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4-48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study. J Microbiol Immunol Infect. 2017 Oct;50(5):684-692. doi: 10.1016/j.jmii.2015.10.003. Epub 2015 Nov 27.

Reference Type BACKGROUND
PMID: 26733351 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CSUB0174

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study Of Atopic Dermatitis In Pediatrics
NCT00257569 COMPLETED PHASE3